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Traumatic brain injury (TBI) often leads to heterogeneous clinical outcomes, which may be 
influenced by genetic variation. A single-nucleotide polymorphism (SNP) in the dopamine D2 
receptor (DRD2) may influence cognitive deficits following TBI. However, part of the association 
with DRD2 has been attributed to genetic variability within the adjacent ankyrin repeat and kinase 
domain containing 1 protein (ANKK1). Here, we utilize the Transforming Research and Clinical 
Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) study to investigate whether a 
novel DRD2 C957T polymorphism (rs6277) influences outcome on a cognitive battery at 6 
months following TBI—California Verbal Learning Test (CVLT-II), Wechsler Adult Intelligence 
Test Processing Speed Index Composite Score (WAIS-PSI), and Trail Making Test (TMT). Results 
in 128 Caucasian subjects show that the rs6277 T-allele associates with better verbal learning and 
recall on CVLT-II Trials 1–5 (T-allele carrier 52.8 ± 1.3 points, C/C 47.9 ± 1.7 points; mean 
increase 4.9 points, 95% confidence interval [0.9 to 8.8]; p = 0.018), Short-Delay Free Recall (T-
carrier 10.9 ± 0.4 points, C/C 9.7 ± 0.5 points; mean increase 1.2 points [0.1 to 2.5]; p = 0.046), 
and Long-Delay Free Recall (T-carrier 11.5 ± 0.4 points, C/C 10.2 ± 0.5 points; mean increase 1.3 
points [0.1 to 2.5]; p = 0.041) after adjusting for age, education years, Glasgow Coma Scale, 
presence of acute intracranial pathology on head computed tomography scan, and genotype of the 
ANKK1 SNP rs1800497 using multivariable regression. No association was found between DRD2 
C947T and non-verbal processing speed (WAIS-PSI) or mental flexibility (TMT) at 6 months. 
Hence, DRD2 C947T (rs6277) may be associated with better performance on select cognitive 
domains independent of ANKK1 following TBI.
Keywords
Traumatic brain injury; Genetic factors; Cognition; Outcome measures; Human studies
Introduction
Traumatic brain injury (TBI) is a significant source of morbidity and mortality—an 
estimated 2.5 million cases occur annually in the USA alone [1] Initial injury severity is 
commonly stratified into severe, moderate, and mild TBI categories as defined by an initial 
Glasgow Coma Scale (GCS) score of 8 or less, 9 to 12, and 13 to 15, respectively [2, 3]. 
Individuals with similar injuries often follow divergent clinical trajectories [4]. Up to 5.3 
million people live with long-term disability from TBI, and numerous others experience 
persistent TBI-related sequelae—including cognitive deficits, changes in personality, and 
increased rates of post-traumatic psychiatric disorders such as depression and/or post-
traumatic stress disorder [5, 6]. However, factors influencing variability in post-traumatic 
clinical course remain unclear and efforts are needed to better identify those at greatest risk 
for post-traumatic sequelae [7].
Studies have begun to suggest that genetic variability—such as single-nucleotide 
polymorphisms (SNPs)—may be one factor which contributes to observed clinical variance. 
A number of polymorphisms influencing protein structure, function, and/or availability have 
been identified [8–11]. In particular, SNPs arising within the dopaminergic system may 
influence cognition and cognitive recovery following TBI [12]. The neurotransmitter 
dopamine is essential for proper neuronal function of the striate nucleus linked to learning 
Yue et al. Page 2
Neurogenetics. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and memory [13]. One important molecular component of dopaminergic signaling pathways 
is the dopamine D2 receptor (DRD2), which is highly expressed in the striatum of the 
subcortical forebrain. DRD2 binds to dopamine in the synaptic cleft and initiates post-
synaptic secondary messenger cascades, which modulate neuronal circuits contributing to 
several cognitive domains, namely learning [14]. Reduced DRD2 expression has been linked 
to cognitive impairment and psychiatric disease [15, 16]. Furthermore, stimulation of DRD2 
in the striatum has been shown to potentiate learning when treated with a D2-specific 
agonist [13, 17].
Given the prevalence of cognitive defects in TBI patients, there is an interest in identifying 
SNPs that associate with poor cognitive outcome [13, 18]. The DRD2 gene is located on 
chromosome 11 q22–23 with a relatively common SNP located within exon 7 with a single-
nucleotide cytosine to thymine substitution—known as the C957T SNP rs6277 [19, 20]. 
This substitution has been associated with decreased affinity of the striatal D2 receptors [21] 
and is associated with better learning, verbal memory, and cognitive ability in the psychiatry 
literature [22–24]. Initial studies report a potential connection between DRD2 C957T and 
cognitive performance following TBI [13, 15, 18]. However, this observation may be 
confounded by linkage effects with ankyrin repeat and kinase domain containing 1 protein 
(ANKK1) TaqIA (rs1800497)—a gene adjacent to and oriented tail to tail with DRD2 on 
chromosome 11 [13, 25]. Therefore, a potential modulatory role of DRD2 C957T on 
cognitive performance remains unclear and warrants further investigation.
For the current analysis, we utilized data from the prospective multicenter Transforming 
Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Pilot study in 
order to explore associations between the DRD2 C957T SNP and cognitive outcomes post-
TBI while controlling for ANKK1 Taq1A [26]. We demonstrate that the DRD2 C957T T-
allele is associated with better performance on verbal memory but not processing speed or 
mental flexibility at 6 months post-TBI.
Methods
Study design
The TRACK-TBI Pilot Study is a multicenter prospective observational study conducted at 
three level I trauma centers in the USA—San Francisco General Hospital, University of 
Pittsburgh Medical Center, and University Medical Center Brackenridge (UMCB) in Austin, 
TX—using the National Institutes of Health (NIH) and National Institute of Neurological 
Disorders and Stroke (NINDS) common data elements (CDEs) [26–30]. Inclusion criteria 
for the pilot study were adult patients presenting to a level I trauma center with external 
force trauma to the head and clinically indicated head computed tomography (CT) scan 
within 24 h of injury. Exclusion criteria were pregnancy, comorbid life-threatening disease, 
incarceration, on psychiatric hold, and non-English speakers due to limitations in 
participation with outcome assessments. For the present study, our goal was to study the 
association of the DRD2 C957T polymorphism on cognitive outcome after TBI 
uncomplicated by massive intracranial injury, neurosurgical intervention, or polytrauma. 
Therefore, our analysis was restricted to a subset of adult patients with Marshall CT Score 
1–2; no acute neurosurgical intervention; no developmental delay; and no severe, critical, or 
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unsurvivable extracranial injuries as defined by an Abbreviated Injury Scale (AIS) score >3 
in any extracranial body region. Due to the small numbers and unequal distribution of DRD2 
C957T genotypes in other races in our sample, all selected patients were of Caucasian race.
Eligible subjects were enrolled through convenience sampling at all three sites. Institutional 
review board approval was obtained at all participating sites. Informed consent was obtained 
for all subjects prior to enrollment in the study. For patients unable to provide consent due to 
their injury, consent was obtained from their legally authorized representative (LAR). 
Patients were then reconsented, if cognitively able at later inpatient and/or outpatient follow-
up assessments for continued participation in the study.
Biospecimen acquisition and genotyping
Specimen acquisition was performed as previously described [30]. In brief, blood samples 
for DNA genotyping analysis were collected via peripheral venipuncture or existing 
peripheral venous indwelling catheters within 24 h of injury. Samples were collected in BD 
Vacutainer K2-EDTA Vacutainer tubes and subsequently aliquoted and frozen in cryotubes 
at −80 °C within 1 h of collection in accordance with recommendations from the NIH-CDE 
Biomarkers Working Group [29]. DNA was extracted from isolated leukocytes using the 
Wizard® Genomic DNA Purification Kit as described by the manufacturer (Promega, 
Madison, WI). The DRD2 C957T (rs6277) and ANKK1 TaqIA (rs1800497) polymorphisms 
were genotyped using the TaqMan® SNP Genotyping Assay as described by the 
manufacturer (Applied Biosystems, Carlsbad, CA; rs6277 Assay ID# C__11339240_10; 
rs1800497 Assay ID# C__7486676_10). For the purposes of evaluating a potential 
protective benefit of the DRD2 C957T T-allele, C/T and T/T individuals were combined as a 
single group as previously described for DRD2 C957T [13, 22, 23]. Therefore, for data 
recording and all figures, this group is referred to as DRD2 C957T T-Present. Likewise, 
ANKK1 TaqIA genotype was dichotomized by T-allele carriers versus non-carriers as 
described previously [13].
Neuropsychiatric testing and outcome parameters
The NINDS defines measures of neuropsychological impairment as those “of 
neuropsychological functions, such as attention, memory, and executive function which are 
very sensitive to effects of TBI that affect everyday activities and social role participation.” 
To evaluate for neuropsychological impairment, all participants underwent outcome 
assessment at 6 months following TBI with a battery of NIH NINDS-designated “Core 
Measures”—those deemed most relevant and applicable across large TBI studies. For the 
current analysis, all three measures of the “neuropsychological impairment” domain of the 
outcome CDEs were included.
California Verbal Learning Test, second edition—The California Verbal Learning 
Test (CVLT)-II is a verbal learning and memory task in which five learning trials, an 
interference trial, an immediate recall trial, and a post-20-min recall trial are performed. The 
CVLT-II was substituted for the Rey Auditory Verbal Learning Test (RAVLT) listed in the 
NIH NINDS outcome CDEs, due to relevant revisions of the second edition and higher 
consistency on between-norm sets as previously described [31, 32]. The CVLT-II Trial 1–5 
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raw score provides a global index of verbal learning ability [33]. Further, lower scores on the 
CVLT-II Short-Delay Free Recall (SDFR) indicate retroactive interference, while lower 
scores on the CVLT-II Long-Delay Free Recall (LDFR) indicate the occurrence of rapid 
forgetting. As outlined, all CVLT raw scores are adjusted for age and years of education as 
part of the current analysis [33].
Wechsler Adult Intelligence Scale, fourth edition, Processing Speed Index 
Subscale—The Wechsler Adult Intelligence Test Processing Speed Index Composite Score 
(WAIS-PSI) is composed of two non-verbal tasks (symbol search and coding) which require 
visual attention and motor speed [34]. The composite score, normalized for age, was used in 
this analysis. On this test, a higher score reflects improved non-verbal processing speeds. In 
prior versions of this test, WAIS III, TBI has demonstrated that the WAIS-PSI predominately 
reflects impairment in perceptual processing speed with a small component attributable to 
working memory and only minimal contribution from motor speed [35]. The WAIS-PSI 
composite score includes adjustment for age and thus is adjusted only for years of education 
as part of the current analysis [34].
Trail Making Test—The Trail Making Test (TMT) is a two-part timed test (TMT-A and 
TMT-B). TMT-A assesses visual processing, and TMT-B assesses mental flexibility and 
processing speed [36]. In order to increase the accuracy of the score with respect to the 
flexibility and processing speed without accounting for visual processing, we subtracted the 
first trial from the second trial (TMT B-A) as previously described [37]. On this test, a lower 
score suggests improved performance. The TMT B minus A score is adjusted for age and 
years of education as part of the current analysis [36].
Statistical analysis
Descriptive variables are presented as means and standard deviations (SDs) for continuous 
variables and as proportions for categorical variables. Group differences in patient 
demographics and injury characteristics across DRD2 C957T genotypes were assessed by 
Pearson’s chi-squared test (X2) for categorical variables and analysis of variance (ANOVA) 
for continuous variables. Fisher’s exact test was used to assess for differences in categorical 
variables with individual cell counts ≤5. Linear regression was performed to assess the 
univariate association between DRD2 C957T genotype and each of the five outcome 
measures, adjusted for age and education years for CVLT measures and TMT B-A, and for 
education years only for WAIS-PSI, as described in the respective “Methods” section 
previously. Multivariable linear regression was performed to adjust for ANKK1 TaqIA 
genotype, gender, post-traumatic amnesia, emergency department admission GCS, and 
intracranial pathology on initial head CT scan for each outcome measure. The adjusted 
means and standard errors (SE) are reported for DRD2 C957T genotypes, and the adjusted 
mean differences (B) and their associated 95% confidence intervals (CI) are reported for 
predictors in each regression analysis. Significance was assessed at α = 0.05. All analyses 
were performed using Statistical Package for the Social Sciences (SPSS) v. 22 (IBM 
Corporation, Chicago, IL).
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Results
Demographic and injury characteristics
In total, 128 subjects were included in the current analysis (Table 1). The majority were 
male (64%) and all self-identified as Caucasian. Mean age was 44.4 ± 16.4 years, and mean 
years of education were 14.3 ± 2.7. Mechanisms of injury included fall (50%), motor vehicle 
accident (25%), pedestrian versus automobile (13%), assault (10%), and struck by object 
(2%). Mean GCS was 13.5 ± 3.2. Injury severity by admission GCS was 85% mild, 5% 
moderate, and 10% severe TBI. Thirty-two percent of patients did not have post-traumatic 
amnesia, while 56% had positive amnesia and 12% were unknown. Thirty-eight percent of 
patients showed positive intracranial pathology on initial head CT. DRD2 C947T (rs6277) 
was distributed with the following ns: C/C = 42, C/T = 58, and T/T = 28 (C-allele frequency 
0.55, T-allele frequency 0.45), conforming to the Hardy-Weinberg equilibrium (X2 = 0.88, p 
> 0.05) and known Caucasian-European (CEU) HapMap distribution (C-allele frequency 
0.53, T-allele frequency 0.47). No statistically significant differences were observed for any 
demographic or clinical descriptor across DRD2 C957T genotypes (Table 1). ANKK1 
TaqIA (rs1800497) was distributed with the following ns: C/C = 79, C/T = 42, and T/T = 7 
(C-allele frequency 0.78, T-allele frequency 0.22), conforming to the Hardy-Weinberg 
equilibrium (X2 = 0.20, p > 0.05) and known CEU HapMap distribution (C-allele frequency 
0.81, T-allele frequency 0.19). The ANKK1 TaqIA polymorphism distributed differently 
across DRD2 C957T; 26/86 (30%) of DRD2 C957T T-allele carriers, versus 23/42 (55%) of 
DRD2 C/C individuals, carried the ANKK1 T-allele (p = 0.007); the lower concurrent 
inheritance of DRD2 C957T T-allele and the ANKK1 TaqIA T-allele is consistent with prior 
reports [25, 38].
DRD2 C957T is associated with verbal memory but not processing speed or mental 
flexibility
We first sought to characterize whether the DRD2 C957T polymorphism was associated 
with global or domain-specific differences in 6-month cognitive performance. DRD2 C957T 
T-allele carriers were found to perform better on CVLT-II Trials 1–5 (mean increase 4.4 
points, 95% CI [0.4 to 8.5], p = 0.033); a non-significant statistical trend was found for 
CVLT-II Short-Delay Free Recall (mean increase 1.1 points, 95% CI [−0.1 to 2.4], p = 
0.073) and Long-Delay Free Recall (mean increase 1.1 points, 95% CI [−0.1 to 2.4], p = 
0.083). No differences were found for TMT B-A (B = −13.6, 95% CI [−31.3 to 4.1], p = 
0.131) or WAIS-PSI (B = 1.3, 95% CI [−4.2 to 6.8], p = 0.639) (Table 2). These data suggest 
that the DRD2 C957T polymorphism is not associated with a global improvement in 
cognitive performance, but rather a specific performance advantage with tasks of verbal 
learning and recall.
DRD2 C957T is associated with verbal memory after multivariable correction
We next sought to evaluate whether the association between the DRD2 C957T 
polymorphism and CVLT-II performance persisted after adjusting for known predictors of 
outcome after TBI. For each of the five outcome measures, DRD2 C957T was entered into a 
multivariable model including ANKK1 TaqIA genotype, gender, presence/absence of post-
Yue et al. Page 6
Neurogenetics. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
traumatic amnesia, admission GCS, and presence/absence of intracranial pathology on CT in 
addition to age and education years.
On multivariable analysis of CVLT-II Trials 1–5, the DRD2 T-allele is associated with 
improved performance compared to non-carriers as evidenced by a mean increase of 4.9 
points (95% CI [0.9 to 8.8], p = 0.018) (Table 3). Male gender showed a mean decrease of 
4.0 points (95% CI [−7.8 to −1.1], p = 0.044), and CT-positive patients had a mean decrease 
of 5.8 points (95% CI [−10.0 to −1.6], p = 0.007). ANKK1 genotype, post-traumatic 
amnesia, and admission GCS did not show significant associations with CVLT-II Trials 1–5.
On multivariable analysis of CVLT-II Short-Delay Free Recall, the DRD2 T-allele showed a 
significant association with improved performance (mean increase 1.2 points, 95% CI [0.1 to 
2.5], p = 0.046). CT pathology was the only other significant multivariable predictor (mean 
decrease 1.7 points, 95% CI [−3.0 to −0.4], p = 0.011) (Table 3).
On multivariable analysis of CVLT-II Long-Delay Free Recall, the DRD2 T-allele showed a 
significant association with improved performance (mean increase 1.3 points, 95% CI [0.1 to 
2.5], p = 0.041). CT pathology was the only other significant predictor (mean decrease 2.0 
points, 95% CI [−3.3 to −0.7], p = 0.002) (Table 3).
DRD2 C957T is not associated with processing speed or mental flexibility after 
multivariable correction
As previously demonstrated (Table 2), no significant differences were observed between the 
DRD2 C957T polymorphism and TMT B-A or WAIS-PSI. To confirm the lack of 
confounder effects, we utilized a similar multivariable approach for TMT B-A and WAIS-
PSI (Table 4). On multivariable analysis, a non-significant statistical trend was observed for 
DRD2 C957T T-carriers on TMT B-A (mean decrease −16.2 s, 95% CI [−34.6 to 2.2], p = 
0.084), while no other predictors showed a significant association. No significant association 
was observed on WAIS-PSI for DRD2 T-allele carriers (mean increase 1.1 points, 95% CI 
[−4.6 to 6.9], p = 0.700) or any other predictor, and only admission GCS showed a non-
significant statistical trend (per-unit increase of 0.8 points, 95% CI [−0.1 to 1.7, p = 0.093). 
These data confirm that the DRD2 C957T polymorphism does not associate with 6-month 
performance on metrics of nonverbal processing speed or mental flexibility.
Discussion
In the present study, we investigated whether the DRD2 C957T polymorphism was 
associated with cognitive performance 6 months following TBI. We show that the DRD2 
C957T polymorphism was associated with better performance on the components of the 
CVLT but was not the WAIS-PSI or the TMT. The CVLT assesses a patient’s ability to store 
new information and is understood to be a gauge of verbal and working memory [33, 39]. 
Thus, our results suggest that the DRD2 C957T polymorphism is specifically associated 
with better verbal and working memory post-TBI and does not offer benefit for processing 
speed and/or mental flexibility. The identification of a potential association with DRD2 and 
cognitive outcome after TBI and the specificity of the effect for verbal and working memory 
are both novel insights advanced by this work.
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Previous efforts to associate DRD2 with altered cognitive performance have been promising 
but inconclusive. In 2005, a study found an association between DRD2 SNPs and altered 
cognitive performance in a post-TBI population [18]. However, these results were 
confounded by the influence of a nearby gene, ANKK1 [13]. It was not known if DRD2 is 
independently associated with long-term altered cognitive performance in a post-TBI 
population. Here, we analyzed subjects’ cognitive performance at 6 months after TBI and 
controlled for the effects of ANKK1. The 6-month time point allowed us to measure long-
term cognitive outcome after TBI and not be overly influenced by transient changes in 
cognition that occur during the recovery period, which usually completes 3 months after 
injury [40, 41]. As noted previously, we found that DRD2 genotype was associated with 
cognitive differences at 6 months when the ANKK1 effects were included in the multivariate 
regression. Thus, these data support the idea that DRD2 C957T may be an independent 
predictor of cognitive outcome after TBI.
A recent study by Failla et al. conducted in 108 severe TBI patients investigating rs6279, a 
gene with considerable linkage disequilibrium with rs6277, suggests that differences 
attributable to the DRD2 C957T polymorphism may not be maintained at 12 months [42]. 
Our findings showing an advantage of DRD2 C957T at 6 months raise questions as to 
whether C957T carriers may endure an altered trajectory of recovery and experience delayed 
recovery sometime within the 6–12-month interval. It also may suggest that the cognitive 
deficits are not altogether permanent. An alternative explanation is that the severity of the 
injury could interact with cognitive recovery. Specifically, the work by Failla et al. focused 
on severe TBI subjects of all races with positive intracranial pathology on CT that received 
treatment from a level I trauma center, whereas our data included data from all TBI patients 
of Caucasian race, with a mixture of CT pathology [42]. The resolving deficit in Failla et al. 
could be due to the extensive treatments that this cohort offered and may not be 
generalizable to all TBI patients [42].
Establishing that the DRD2 polymorphism is associated with cognitive outcome after TBI 
also may explain the variability in response to dopamine therapy after TBI. Indeed, there 
have been six randomized controlled trials examining the role of amantadine and/or 
bromocriptine (both dopamine-enhancing agents) in cognitive recovery after TBI; the results 
have not shown a consistent benefit of dopamine agents in cognitive recovery and are often 
discordant [43]. However, here, we show that the presence of DRD2 polymorphisms may 
influence cognitive recovery after TBI, and it is very likely that the effect of dopamine 
agents will be heavily influenced on their presence as well as those of related 
polymorphisms in dopaminergic catabolic biochemical pathways—such as catechol-o-
methyltransferase. Thus, we recommend that future studies examining dopamine agents as a 
treatment for TBI stratify patients based on the presence of the DRD2 genotype, which may 
clarify the role of dopamine therapy in TBI.
Aside from establishing a potential association between DRD2 and cognitive outcome after 
TBI, we also show that DRD2 C957T may specifically associate with improved verbal and 
working memory. This specificity is important because it shows that DRD2 genotype likely 
does not enhance global cognitive ability, such as attention and awareness, which may 
covary with many different cognitive outcomes. Instead, there may be a specific link 
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between DRD2 and verbal and working memory. This link can be explained by the fact that 
the D2 dopamine receptor has enriched expression in the basal ganglia, a region important in 
learning and memory [44]. Furthermore, dopaminergic neurons in the basal ganglia 
(substantia nigra pars compacta) project directly to the prefrontal cortex and the 
hippocampus, regions that have been heavily implicated in working and verbal memory, 
respectively [45].
Limitations
Our results provide a link between the genetic, neuroscience, and psychological markers of 
cognitive dysfunction after TBI. However, there are a number of caveats that should be 
mentioned. First, although it has been speculated that patients’ genotypes can alter the 
magnitude dopamine expression and dopamine binding, which could change the course of 
their recovery [46], other studies have shown that C957T is associated with increased risk 
for some neuropsychiatric diseases [25, 47]. Therefore, it is not clear if different DRD2 
genotypes confer a baseline difference in CVLT performance or if they signify altered 
performance after TBI. Second, our sample consisted exclusively of Caucasian patients, and 
consequently, our findings may not generalize to the population as a whole. Third, we only 
considered patients’ GCS score when producing our multivariable models. These models, 
therefore, did not factor in possible disparate courses of prior medications, post-injury 
medical treatment, or rehabilitative therapy. Furthermore, we were limited by a relatively 
small sample size of 128 patients without controls. While the NINDS CDE outcome 
domains are generally distinct, the possible overlap across cognitive symptomatologies 
attributable to DRD2 C957T will benefit from a rigorous case-control study adequately 
powered to adjust for a range of comparisons. We were also constrained to specifications of 
the NINDS CDE version 1, which were limited to 6 months post-injury; as cognitive deficits 
following TBI may change with time after injury, an analysis tracking the trajectory of 
recovery for DRD2 C957T variants constitutes an important future direction. Lastly, the true 
effect of DRD2 variants is difficult to establish due to presumed gene-gene interactions. The 
genetic variation in DRD2 genes may interact with effects induced by other genes important 
for cognitive recovery.
Conclusions
The DRD2 C957T polymorphism (rs6277) is associated with verbal memory performance at 
6 months following TBI independent of the ANKK1 TaqIA polymorphism (rs1800497), 
while no associations were seen on measures of non-verbal processing speed or mental 
flexibility, in a sample of Caucasian patients. Larger studies in more diverse populations will 
be necessary to confirm the influence of DRD2 C957T in these and other outcome domains 
following TBI. Whether a subgroup of patients with the DRD2 C957T polymorphism may 
benefit from closer clinical surveillance or targeted dopaminergic therapies remains to be 
determined and constitutes an important direction for future research.
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Table 1
Demographic and clinical characteristics of included patients, by DRD2 C957T genotype
Variable Overall (N = 128) T-Present (N = 86) T-Absent (N = 42) Sig. (p)
Age (years)
 Mean, SD 44.4 ± 16.4 45.1 ± 16.7 43.1 ± 15.9 0.527
Gender
 Male 82 (64%) 57 (66%) 25 (60%) 0.455
 Female 46 (36%) 29 (34%) 17 (40%)
Education (years)
 Mean, SD 14.3 ± 2.7 14.4 ± 2.8 14.0 ± 2.7 0.460
Mechanism of injury
 Motor vehicle crash 32 (25%) 22 (26%) 10 (24%) 0.964
 Pedestrian versus auto 26 (13%) 11 (13%) 5 (12%)
 Fall 64 (50%) 42 (49%) 22 (54%)
 Assault 13 (10%) 8 (9%) 5 (12%)
 Struck by 2 (2%) 2 (2%) 0 (0%)
Post-traumatic amnesia
 No 41 (32%) 30 (35%) 11 (26%) 0.371
 Yes 72 (56%) 48 (56%) 24 (57%)
 Unknown 15 (12%) 8 (9%) 7 (17%)
ED arrival GCS
 Mean, SD 13.5 ± 3.2 13.6 ± 3.2 13.4 ± 3.3 0.756
 Severe (3–8) 13 (10%) 10 (12%) 3 (7%)
 Moderate (9–12) 6 (5%) 1 (1%) 5 (12%)
 Mild (13–15) 109 (85%) 75 (87%) 34 (81%)
CT intracranial pathology
 No 79 (62%) 54 (63%) 25 (60%) 0.721
 Yes 49 (38%) 32 (37%) 17 (40%)
ANKK1 TaqIA genotype
 T-Present 49 (38%) 26 (30%) 23 (55%) 0.007
 T-Absent 79 (62%) 60 (70%) 19 (45%)
All distributions are reported as column percentages
CT computed tomography, DRD2 dopamine receptor D2, ED emergency department, GCS Glasgow Coma Scale, SD standard deviation
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